Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/2005
11/01/2005US6960692 Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
11/01/2005US6960683 Antiinflammatory agents; autoimmune diseases; cardiovascular disorders
11/01/2005US6960609 Analgesics; central nervous system disorders; gastrointestinal disorder; therapy for drug abruse ; antiinflammatory agents
11/01/2005US6960602 Piperidine derivatives as modulators of chemokine receptors
11/01/2005US6960597 Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
11/01/2005US6960587 Piperido(1,2-a)piperazine-1,4-dione derivatives fused to a 5-7 membered ring at the 7-8 position; cGMP-specific PDE inhibitors; treatment of cardiovascular disorders and erectile dysfunction.
11/01/2005US6960585 For therapy of inflammatory and immune diseases
11/01/2005US6960581 1-amino-2-hydroxy-butane or 2-hydroxy-butanamide derivatives
11/01/2005US6960569 Hepatitis C virus non-structural NS3/4A fusion gene
11/01/2005US6960563 Spontaneous emulsions containing cyclosporine
11/01/2005US6960469 Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain
11/01/2005US6960441 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cancer, inflammation and infections; for use as cosmetic, pesticide and antibiotic
11/01/2005US6960359 Comprising cedrol, cedrenol, farnesol, patchouli alcohol or vetiverol; antiallergic agents and atopic dermatitis preventives
11/01/2005US6960344 Use of imine-forming polysaccharides as adjuvants and immunostimulants
11/01/2005CA2442066C Pd-1, a receptor for b7-4, and uses therefor
11/01/2005CA2383351C Xanthine derivatives as selective antagonists of a2b adenosine receptors
11/01/2005CA2372639C Deuterated cyclosporine analogs and their use as immunomodulating agents
10/2005
10/29/2005CA2564988A1 Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases
10/28/2005CA2564855A1 Compositions and methods for mucosal vaccination
10/27/2005WO2005100987A1 Novel ligand of g protein coupled receptor protein and use thereof
10/27/2005WO2005100563A1 Follistatin mutant polypeptide
10/27/2005WO2005100560A1 Cell death inducer
10/27/2005WO2005100558A1 Cd40 ligand mutant and utilization of the same
10/27/2005WO2005100374A1 Therapeutic heparins and their binding to interleukins 4 and 5, and pecam-1
10/27/2005WO2005100341A1 2-aminopyridine derivative
10/27/2005WO2005099759A1 Medicine for prevention and/or treatment of arteriosclerosis
10/27/2005WO2005099755A2 Methods of treating autoimmune and inflammatory diseases
10/27/2005WO2005099686A1 Edible composition having effects of promoting the production and release of calcitonin gene-related peptide
10/27/2005WO2005099685A1 Liquid external preparation containing sodium cromoglycate
10/27/2005WO2005007699A8 Human antibody molecules for il-13
10/27/2005WO2004078940A8 USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1
10/27/2005WO2003023008A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/27/2005US20050240035 polymerase inhibitors such as -1-(5-Cyano-pyridin-2-yl)-3-(1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-1-yl)-urea, used as antiviral agents
10/27/2005US20050240009 T-cell epitopes in staphylococcal enterotoxin b
10/27/2005US20050240006 Cytoplasmic region with more than 107 or less than 104 amino acids, a transmembrance region, and an extracellular region; nucleic acids and antibodies; diagnosing hematopoietic cell malignancy or autoimmune disease
10/27/2005US20050239852 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
10/27/2005US20050239834 Novel 4-diphenylmethyl piperidine derivatives
10/27/2005US20050239824 Triple monoamine reuptake inhibitors for the treatment of chronic pain
10/27/2005US20050239815 Receptor or non-receptor; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor
10/27/2005US20050239813 Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases
10/27/2005US20050239802 E.g., 6-{2-[5-Chloro-2-(2,4-difluorobenzyloxy)- phenyl]cyclopent-1-enyl}-pyridine-2-carboxylic acid, used to treat prostaglandin mediated diseases that include inflammatory, neuropathic or visceral pain
10/27/2005US20050239777 Quinazoline derivatives and pharmaceutical compositions containing them
10/27/2005US20050239776 Tachykinin receptor antagonists
10/27/2005US20050239773 1-[9-(3-Phenyl-allyl)-3,9 diaza-bicyclo[4.2.1]non-3-yl]-propan-1-one; analgesic; great selectivity to mu receptor; analgesic; pain relief, drug dependence, alcoholism; side effect reduction
10/27/2005US20050239732 Immunostimulatory nucleic acid molecules
10/27/2005US20050239170 Alpha-MSH related compounds and methods of use
10/27/2005US20050239141 Modified antibody variable domains
10/27/2005US20050239103 Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof
10/27/2005US20050239099 27 human secreted proteins
10/27/2005US20050238670 Immunology response intensifiers; administering a bacterial lysate, for inducing an immune response to Staphylococcus aureus infections
10/27/2005US20050238637 Vectors for molecule delivery to CD11b expressing cells
10/27/2005CA2564878A1 Therapeutic heparins and their binding to interleukins 4 and 5, and pecam-1
10/27/2005CA2563260A1 Methods of treating autoimmune and inflammatory diseases
10/27/2005CA2562892A1 Bob-1 specific t cells and methods to use
10/27/2005CA2562885A1 Follistatin variant polypeptide
10/27/2005CA2562602A1 2-aminopyridine derivative
10/27/2005CA2562369A1 Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
10/27/2005CA2561364A1 Steroid sparing agents and methods of using same
10/26/2005EP1589108A2 Methods and reagents for vaccination which generate a CD8 T cell immune response
10/26/2005EP1589107A1 Immunoglobulins devoid of light chains
10/26/2005EP1589031A2 Production of polyketides and other natural products
10/26/2005EP1589007A2 5-membered heterocycle derivatives, production thereof and their use as medicaments
10/26/2005EP1588714A2 Adjuvant systems and vaccines
10/26/2005EP1588712A1 Modulators of regulatory proteins
10/26/2005EP1587838A2 Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
10/26/2005EP1587834A2 Uses of mammalian cytokine; related reagents
10/26/2005EP1587812A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease
10/26/2005EP1587811A1 Thienopyridazinones and their use in modulation of autoimmune disease
10/26/2005EP1587542A1 Use of anti-cd100 antibodies
10/26/2005EP1587541A2 Compositions and methods of tolerizing a primate to an antigen
10/26/2005EP1587534A1 Use of tff2, or agents inducing tff2, in the therapy of allergies
10/26/2005EP1587528A2 Methods of treating and/or preventing autoimmune diseases
10/26/2005EP1587521A1 Bioavailability enhancing activity of carum carvi extracts and fractions thereof
10/26/2005EP1587483A2 Methods for modulating an inflammatory response
10/26/2005EP1587482A2 Anti-inflammatory compositions and uses thereof
10/26/2005EP1151010B1 Human polyclonal antibodies from transgenic nonhuman animals
10/26/2005EP1098870B1 Nitrate salt of Cetirizine
10/26/2005EP0951289B1 Use of mycobacterium vaccae for treating chronic fatigue syndrome
10/26/2005CN1688604A Recombinant anti-osteopontin antibody and use thereof
10/26/2005CN1688603A Treatment and prophylaxis with 4-1BB-binding agents
10/26/2005CN1688580A Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
10/26/2005CN1688578A Phosphodiesterase 4 inhibitors
10/26/2005CN1688577A Triazaspiro [5.5] undecane derivatives and drugs comprising the same as the active ingredient
10/26/2005CN1688550A 2, 5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
10/26/2005CN1688548A Process for preparing quinolin antibiotic intermediates
10/26/2005CN1688532A Composition based on substituted 1, 3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
10/26/2005CN1224707C Intracellular isoform of the interleukin-1 receptor antagonist
10/26/2005CN1224704C Preparing method for recombinant chBJSTWO protein
10/26/2005CN1224623C 1-phenysulfonyl-1, 3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use
10/26/2005CN1224612C Acetylenic sulfonamide thiol TACE inhibitors
10/26/2005CN1224422C Vaccines comprising interleukin-12 and herpes simplex viral antigen
10/26/2005CN1224419C Orally administered peptides to ameliorate a therosclerosis
10/26/2005CN1224418C Biological preparation containing marine active substance and use thereof
10/25/2005US6958387 Human serpin polypeptides
10/25/2005US6958350 Chemical compounds
10/25/2005US6958349 Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
10/25/2005US6958344 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/25/2005US6958336 Anticancer agents; immunosuppressants; antiallergens; antiinflammatory agents
10/25/2005US6958331 sulfonyl amine derivatives such as {2-(2,2-diphenyl-ethylamino)-5-[4-(4-isopropyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone; pain, inflammation, septic shock
10/25/2005US6958319 Stability and longer shelf life; bortezomib N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid
1 ... 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 ... 1172